Bio-technologies for a glandular stem cell cardiomyopexy.
The glandular stem cell cardiomyopexy should become a treatment option for end-stage heart failure. It combines an expected regenerative potential of transformed adult glandular stem cells into cardiomyocytes within the myocardium or onto the myocardium of the recipient and the potential of a hypercapillarized latissimus dorsi muscle (LDM) wrapped around the heart for stem cell nutrition and girdling.
Guldner
Norbert W
NW
Cardiac Surgery Division, University Hospital of Schleswig Holstein, Campus Luebeck, Ratzeburger Allee 160, D-23538 Luebeck, Germany. guldner@medinf.mu-luebeck.de
Klapproth
Peter
P
Schwarz
Philipp O
PO
Hardel
Tim
T
Rumpf
Philipp M
PM
Kajahn
Jenny
J
Margaritoff
Petra
P
Sievers
Hans H
HH
Grossherr
Martin
M
D000328:Adult; D000818:Animals; D001709:Biotechnology / Q000379:methods*; D002454:Cell Differentiation; D006041:Goats; D006333:Heart Failure / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D032383:Myocytes, Cardiac / Q000166:cytology / Q000473:pathology; D010179:Pancreas / Q000166:cytology; D010306:Parotid Gland / Q000166:cytology; D012038:Regeneration / Q000502:physiology*; D033581:Stem Cell Transplantation / Q000379:methods*; D013234:Stem Cells / Q000166:cytology* / Q000502:physiology*